Depression News

The Patient-Centered Outcomes Research Institute has announced $96 million in funding for 18 new studies that will focus on mental health, delirium and adolescent alcohol use.

Mindfulness-based stress reduction was found to be noninferior to escitalopram for the treatment of anxiety disorders, researchers reported in JAMA Psychiatry.

Videra Health has announced a partnership with Signature Healthcare Services to improve the post-discharge follow-up experience by using AI-assisted video assessments for those with behavioral health issues.

According to a recently released survey, 38% of Americans revealed their overall mood declines in the winter but added that traditions related to the upcoming holidays impacts their mood positively.

A 25 mg dose of psilocybin was associated with improvements in treatment-resistant depression over a 3-week period, but with adverse events, a recent study found.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

Depression was associated with a lower likelihood of having children and of having fewer children for adults in Finland, according to data published in the American Journal of Obstetrics & Gynecology.

Digital health solutions company Twill has announced a partnership with e-Psychiatry, a telepsychiatry and teletherapy service, that it says will provide increased human and digital mental health support for patients.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

Biomind Labs Inc. has announced positive initial results from the first part of its phase 2 trial of a novel liquid inhaled formulation of N,N-Dimethyltryptamine, or DMT, for treatment-resistant depression.